GlassScriptPhysician profile
Peter Dehnel
NPI 1184604407
$54,028.85
in general payments reported to CMS, 2019-2025
11 companies · $4,026 in 2025
The $4,026 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2021: $1,350 · 2022: $3,600 · 2023: $5,827 · 2024: $13K · 2025: $4,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $2,692 · Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,983.70 |
| Travel and Lodging | $2,691.76 |
| Food and Beverage | $411.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $12,570.81 | 2019 | |
| Amgen INC. | $8,350.00 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $7,689.25 | 2023-2025 | Lynozyfic |
| Glaxosmithkline, LLC. | $7,125.00 | 2023-2025 | Zejula, Nucala |
| Leo Pharma INC. | $3,948.61 | 2024 | |
| Ptc Therapeutics, INC. | $3,556.54 | 2019 | |
| Kite Pharma, INC. | $2,903.28 | 2019 | |
| Incyte Corporation | $2,497.50 | 2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $1,827.00 | 2023 | |
| Seagen INC. | $1,800.00 | 2022 | |
| Gilead Sciences, INC. | $1,760.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dehnel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.